AlphAIAlphAI — Financial news for AI agents
newsable.asianetnews.comSEP 142 min read$IBRX

IBRX Stock Gains As Soon-Shiong’s Nant Capital Backs Second Cancer-Immunotherapy Bet

ImmunityBio (IBRX) shares rose 6% after Nant Capital, led by IBRX founder Soon-Shiong, invested $11.3M in PDS Biotech (PDSB), with an option to license PDS0101. PDSB shares surged 35%. The deal ties Soon-Shiong to another immunotherapy platform, extending his cytokine and cancer-vaccine strategy. Proceeds will support PDSB's debt repayment and late-stage development.

Original reporting
newsable.asianetnews.com
Published Sep 14, 2026, 11:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 6:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
IBRX Stock Gains As Soon-Shiong’s Nant Capital Backs Second Cancer-Immunotherapy Bet — source image
Source · newsable.asianetnews.com
Decision brief

The 30-second read

$IBRXBullishMed
01

Why it matters

The $22.3M financing ties a new HPV‑targeted immunotherapy to the IBRX ecosystem, potentially expanding its pipeline and market perception.

02

Market read

First‑report of a sizable PIPE for a micro‑cap biotech, directly moving IBRX stock and signaling further pipeline development.

03

What to watch

Future funding milestones depend on FDA filing; any delay could stall the anticipated capital benefits.

Relevance 7/10Novelty 7/10Timing: after‑hours Monday

Background

ImmunityBio (IBRX) is a biotech focused on bladder cancer therapy; its founder Patrick Soon‑Shiong frequently backs related ventures.

Company-level read

Ticker impact

$IBRXBullishHigh confidence
Context

IBRX rose 6% after a Nant Capital‑led $22.3M PIPE into PDS Biotech, linking the founder's new immunotherapy platform to ImmunityBio.

Expected impact

Potential further upside if the PDS partnership progresses; watch for volatility on trial updates.

Evidence & confidence

New capital raise of material size for a micro‑cap, first‑report disclosure, and immediate price reaction indicate a strong short‑term catalyst.

Market effects

Sector

Highlights growing investor interest in niche cancer‑immunotherapy platforms, may boost related biotech peers.

Regional

Limited to US biotech sector; no broader regional effect.

Global

Modest, as the deal underscores the role of founder‑backed financing in emerging biotech pipelines.

Counterpoint

What could challenge this read

The PIPE may dilute existing shareholders and the partnership is not a guaranteed license, posing downside risk.

Key entities

  • Company
    ImmunityBio Inc.

    US‑listed biotech (ticker IBRX) developing cancer immunotherapies.

  • Company
    PDS Biotech

    Developer of HPV‑targeted immunotherapy (PDS0101) receiving the PIPE.

  • Investment Vehicle
    Nant Capital

    Founder Patrick Soon‑Shiong's investment arm leading the financing.

Read at source← All news

Related articles

SEP 5
$IBRXMedAI 8/10

IBRX Stock Eyes Best Week Since February: Founder Highlights New Anktiva-NK Cell Therapy Study

ImmunityBio (IBRX) shares are up 9% this week, despite a Q1 net loss of $632.8M and a 7% drop post-earnings. The company's founder highlighted a decade-old study showing safety and efficacy of NK-92 cells, and plans for a new Anktiva combination trial. Anktiva saw 168% revenue growth and is now available in Saudi Arabia. The FDA is reviewing Anktiva's supplemental application, with a decision expected soon.

stocktwits.com3 min
AUG 23
$SLSHighAI 8/10

SLS, IBRX Stocks In Focus: Analyst Says Moderna-Merck Cancer Vaccine Success ‘Bodes Well’ For Oncology

Moderna (MRNA) and Merck (MRK) reported positive Phase 3 trial results for their cancer vaccine, Intismeran Autogene, boosting shares. Analysts raised sales forecasts and approval probabilities. Sellas Life Sciences (SLS) and ImmunityBio (IBRX) are also in focus due to their oncology work. MRNA surged 177%, MRK gained 13%, and other related stocks saw significant moves.

stocktwits.com2 min
AUG 4
$IBRXMedAI 8/10

ImmunityBio, Inc. (IBRX): Results of Operations and Financial Condition

ImmunityBio, Inc. (IBRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million • Q2 2026 net product revenue of $50.7 million, up 92% year-over-year and 15% sequentially from Q1 2026, marking the eighth con

SEC EDGAR 8-K6 min
JUL 30
$IBRXMedAI 8/10

ImmunityBio Achieves World's Broadest Bladder Cancer Approval as UAE Green Lights Lead Drug - ImmunityBio

Emirates Drug Establishment approved ImmunityBio’s (NASDAQ:IBRX) ANKTIVA in the UAE for BCG-unresponsive non-muscle invasive bladder cancer, allowing a 0.4 mg intravesical dose with BCG across the full NMIBC spectrum. It also approved a 1.2 mg subcutaneous dose with checkpoint inhibitors for metastatic NSCLC. QUILT-3.032 reported 71% CIS complete response; QUILT-3.055 median OS was 14.6 months. IBRX shares rose 5.49% to $7.20.

benzinga.com3 min